Back

Can-Fite reports H1 2026 progress as pancreatic study meets safety endpoint

Verifying
  • Can-Fite BioPharma reported H1 2026 clinical updates and financial results.
  • Can-Fite recorded a $4.60 million net loss for the six-month period.
  • Can-Fite expects psoriasis interim-analysis results during Q1 2027.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.